Pacific Mesothelioma Center Moves Closer to Treatment Breakthrough

Thoracic surgeon Dr. Robert Cameron and the Pacific Mesothelioma Center moved closer to a major treatment advance by obtaining U.S. patent approval for their novel mesenchymal stem cell research program. The patent approval in February makes the research program more attractive to potential investors who could accelerate development and change the way malignant mesothelioma is treated. “This is a big deal in the developmental path for MSC [mesenchymal stem cell] therapy,” Patent Adviser Dr. Walid Sabbagh told The Mesothelioma Center at Asbestos.com. “The patent is a pathway to really help these cancer patients. It becomes a platform for the future.” Mesenchymal stem cells already are used to treat some autoimmune diseases. The center’s research program is now testing them as a vehicle to carry molecular and gene therapies directly to the mesothelioma tumor sites. “This cutting-edge strategy has the potential both to increase the chance of long-term survival and eliminate current treatments, such as radiation and chemotherapy, that come with significant side effects,” said Cameron, scientific advisor at the center and director of the UCLA Mesothelioma Program. Killing Tumor Cells Left Behind Cameron is a renowned pleural mesothelioma specialist who pioneered the aggressive, lung-sparing pleurectomy and decortication surgery that many of his peers across the country use today. He also serves as chief of thoracic surgery at the VA Wes...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

Authors: Wu R, Li XY, Wang WH, Cai FF, Chen XL, Yang MD, Pan QS, Chen QL, Zhou RY, Su SB Abstract To investigate the mechanism of a Bushen-Jianpi decoction (BSJPD) in liver cancer (LC) treatment, we analyzed clinical therapy data, conducted network pharmacology analysis, and performed pharmacological experimental verification in vitro and in vivo. The univariate analysis of clinical therapy showed that the BSJPD was protective factor (p
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
Publication date: Available online 25 April 2019Source: Stem Cell ResearchAuthor(s): Junjie Hong, Miao Xu, Rong Li, Yu-Shan Cheng, Jennifer Kouznetsova, Jeanette Beers, Chengyu Liu, Jizhong Zou, Wei ZhengAbstractMucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome, is a rare X-linked genetic disease caused by mutations in the IDS gene encoding iduronate 2-sulfatase (I2S). This is a multisystem disorder with significant variation in symptoms. Here, we document a human induced pluripotent stem cell (iPSC) line generated from dermal fibroblasts of a patient with Hunter syndrome containing a hemizygous mutatio...
Source: Stem Cell Research - Category: Stem Cells Source Type: research
We report the generation of the iPSC line LEIi005-B from a patient with retinitis pigmentosa caused by a dominant nonsense mutation in the RP1 gene (c.2098G>T p.E700X). Reprogramming of dermal fibroblasts was performed using episomal plasmids containing OCT4, SOX2, KLF4, L-MYC, LIN28, mir302/367 microRNA and shRNA for p53 to establish the clonal iPSC line LEIi005-B. LEIi005-B expressed pluripotent stem cell markers, had a normal karyotype and differentiated into endoderm, mesoderm and ectoderm.
Source: Stem Cell Research - Category: Stem Cells Source Type: research
Publication date: Available online 25 April 2019Source: Stem Cell ResearchAuthor(s): Samantha B. Ross, Mira Holliday, Seakcheng Lim, Christopher SemsarianAbstractCatecholaminergic polymorphic ventricular tachycardia (CPVT) is an arrhythmia syndrome characterized by adrenaline induced ventricular tachycardia. The primary genetic aetiologies underlying CPVT are either autosomal dominant or autosomal recessive inheritance, resulting from heterozygous mutations in cardiac ryanodine receptor (RYR2) and homozygous mutations in cardiac calsequestrin-2 (CASQ2), respectively. Recently, a large family with autosomal dominant CPVT du...
Source: Stem Cell Research - Category: Stem Cells Source Type: research
CONCLUSION: miR-362 may be a prognostic marker in CRC and suppress CRC cell proliferation and invasion in part through targeting the 3'-UTR of SIX1 mRNA. The newly identified miR-362/SIX1 axis provides insight into the progression of CRC. PMID: 31016902 [PubMed - in process]
Source: Yonsei Medical Journal - Category: Universities & Medical Training Authors: Tags: Yonsei Med J Source Type: research
Publication date: Available online 25 April 2019Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): D.M. Monti, G. Ferraro, A. MerlinoAbstractThe encapsulation of anticancer metal-based drugs within a protein nanocage represents a valuable strategy to improve the efficacy and selectivity of these compounds towards cancer cells. The preparation, characterization of the in vitro cytotoxicity and X-ray structures of several ferritin-metallodrug nanocomposites (mainly containing platinum-, ruthenium- and gold-based anticancer agents) are here reviewed. The molecular mechanisms of action of these Ft-metallodrug...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research
In conclusion, our studies suggest that silica nanoparticles can mediate the delivery of miR-34a directly into mammary tumors while preserving its molecular and biological activity.Graphical AbstractmiR-34a is efficiently delivered by SiO2 nanoparticles and it inhibits tumor growth.
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research
Publication date: Available online 25 April 2019Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Zhijian Luo, Mingxing Li, Meiling Zhou, Huayun Li, Youyou Chen, Xiaoqun Ren, Yan DaiAbstractHerein, a novel nano-system IF7-ROSPCNP, which is O2-evolving and reactive oxygen species (ROS)-activable, was developed for enhancing the combination chemotherapy and photodynamic therapy (PDT). The nanoparticles composed of photosensitizers (disulfonated meso-tetraphenylporphine, TPPS2a) and catalase in the inner core, doxorubicin (DOX) in the polymeric shell and functionalized on its surface with IF7 peptide, which...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research
Publication date: Available online 25 April 2019Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Ci Ren, Xiaomin Li, Lu Mao, Jinfeng Xiong, Chun Gao, Hui Shen, Liming Wang, Da Zhu, Wencheng Ding, Hui WangAbstractGene therapy targeted human papillomavirus (HPV) is a promising treatment for cervical cancer, and the key for clinical application depends on an effective gene delivery method. Our aim was to formulate a new pharmaceutical formula for appropriate gene delivery intravaginally. For the first time, we here developed a new polyethylenimine (PEI) based vaginal suppository. The sectional immunofluore...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research
In conclusion, the proposed framework is suit for multi-classification tasks of gastric M-NBI images.
Source: Neurocomputing - Category: Neuroscience Source Type: research
More News: Asbestosis | Autoimmune Disease | Cancer | Cancer & Oncology | Cancer Therapy | Cardiology | Cardiovascular & Thoracic Surgery | Chemotherapy | Environmental Health | Funding | Gene Therapy | Genetics | Heart | Laboratory Medicine | Lung Cancer | Mesothelioma | Spinal Cord Injury | Stem Cell Therapy | Stem Cells